Top Markets
Coin of the day
Mural Oncology plc Mural Oncology plc

Mural Oncology plc

MURA
株式のランク #27070
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and... Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.
株価
$2.04
最終同期: 2025-12-09
時価総額
$35.38M
変化(1日)
0.00%
変化(1年)
-2.39%
IE
取引 Mural Oncology plc (MURA)

カテゴリー

Mural Oncology plc(MURA)の配当利回りの履歴
Mural Oncology plc(銘柄コード: MURA)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Mural Oncology plc(MURA)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)